Medical treatment of epithelial ovarian cancer

Expert Review of Anticancer Therapy

Volumn 4, Issue 6, 2004, Pages 1125-1143

  González Martín, Antonio J ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Chemotherapy; Ovarian carcinoma; Review

Indexed keywords

ALTRETAMINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MELPHALAN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TOPOTECAN;

ALOPECIA; BONE MARROW DISEASE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; DRUG INDICATION; ENTEROPATHY; EUROPE; FEMALE; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HIGH RISK PATIENT; HUMAN; HYSTERECTOMY; KIDNEY DISEASE; LEUKOPENIA; MEDICAL DECISION MAKING; META ANALYSIS; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; OVARIECTOMY; OVARY CARCINOMA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PROGNOSIS; QUALITY OF LIFE; REVIEW; SALPINGOOOPHORECTOMY; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; UNITED STATES;

EID: 10644226924     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.6.1125     Document Type: Review

References (71)

1. Jemal A, Tiwari RC, Murray T et al. Cancer statistics 2004. CA Cancer J. Clin. 54, 8-29 (2004).
2. Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Results of a National Ovarian Cancer Survey. Cancer 89, 2068-2075 (2000).
3. Ahmed FY, Wilshaw E, A'Hern RP et al. Natural history and prognosis of untreated Stage I epithelial ovarian carcinoma. J. Clin. Oncol. 14, 2968-2975 (1996).
4. Vergote I, De Brabanter J, Fyles A et al. Prognostic importance of degree of differentiation and cyst rupture in Stage I invasive epithelial ovarian cancer. Lancet 357, 176-182 (2001).
5. Tropé C, Kaern J, Hogberg T et al. Randomized study on adjuvant chemotherapy in Stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann. Oncol. 11, 282-288 (2000).
6. 32P). Ann. Oncol. 6, 887-893 (1995).
7. 32P or intravenous cyclophosphamide and cisplatin - a Gynecology Oncology Group Study. J. Clin. Oncol. 21, 4350-4355 (2003).
8. Bell J, Brady M, Lage J et al. A randomized Phase III trial of three versus six cycles of carboplatin and paclitaxel as adjuvant treatment in early stage ovarian epithelial carcinoma: a Gynecologic Oncology Group Study. Gynecol. Oncol. 88, 156 (2003).
9. Trimbos JB, Vergote I, Bolis G et al. Impact of adjuvant chemotherapy and surgical staging in early stage ovarian carcinoma: European Organization for Research and Treatment of Ovarian Adjuvant Chemotherapy in Ovarian Neoplasm Trial. J. Natl Cancer Inst. 95, 113-125 (2003).
10. International Collaborative Ovarian Neoplasm Trial 1. Randomized trial of adjuvant chemotherapy in women with early stage ovarian cancer. J. Natl Cancer Inst. 95, 125-132 (2003).
11. Trimbos JB, Parmar M, Vergote I et al. International Collaborative Ovarian Neoplasm Trial I and Adjuvant Chemotherapy in Ovarian Neoplasm Trial: two parallel randomized Phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J. Natl Cancer Inst. 95, 105-112 (2003).
12. Young RC, Walton LA, Ellenberg SS et al. Adjuvant therapy in Stage I and II epithelial ovarian cancer. Results of two prospective randomized trials. N. Engl. J. Med 322, 1021-1027 (1990).
13. Vergote IB, Vergote-De Vos LN, Abeler VM et al. Randomized trial comparing cisplatin with radioactive phosphorus or whole abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 69, 741-749 (1992).
14. Hoskins WJ, Bundy BN, Thigpen JT et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. 47, 159-166 (1992).
15. Hoskins WJ, McGuire WP, Brady MF et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obst. Gynecol. 170, 974-980 (1994).
16. Allen DG, Heintz AP, Touw FW. A meta-analysis of residual disease and survival in Stage III and IV carcinoma of the ovary. Eur. J. Gynaecol. Oncol. 16, 349-356 (1995).
17. Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum-era: a meta-analysis. J. Clin. Oncol. 20, 1248-1259 (2002).
18. Junor EJ, Hole DJ, McNulty L et al. Specialist gynaecologist and survival outcome in ovarian cancer a Scottish national study of 1866 patients. Br. J. Obstet. Gynaecol. 106, 1130-1136 (1999).
19. Advanced Ovarian Cancer Trialists' Group. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patients from 37 randomized trials. Br. J. Cancer 78, 1479-1487 (1998).
20. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and IV ovarian cancer. N. Engl. J. Med. 334, 1-6 (1996).
21. Piccart M, Bertelsen K, James K et al. Randomized Intergroup trial of cisplatin-paclitaxel vs. cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: 3 years results. J. Natl Cancer Inst. 92, 699-708 (2000).
22. Muggia FM, Braly PS, Brady MF et al. Phase III randomized study of cisplatin vs. paclitaxel vs. cisplatin and paclitaxel in patients with suboptimal Stage III or IV ovarian cancer. A GOG study. J. Clin. Oncol. 18, 106-115 (2000).
23. Sandercock J, Parmar MKB, Torri V. First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence. Br. J. Cancer 78, 1471-1478 (1998).
24. The ICON collaborators. ICON2: randomised trial of single agent carboplatin against three drug combination of CAP (cyclophosphamide-doxorubicin and cisplatin) in women with ovarian cancer. Lancet 352, 1571-1576 (1998).
25. The International Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360, 505-515 (2002).
26. Neijt JP, Engelholm SA, Tuxen MK et al. Exploratory Phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J. Clin. Oncol. 18, 3084-3092 (2000).
27. du Bois A, Lück H-J, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl Cancer Inst. 95, 1320-1330 (2003).
28. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected Stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21, 3194-3200 (2003).
29. Covens A, Carey M, Bryson P et al. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with Stage II, III, or IV epithelial ovarian cancer. Gynecol. Oncol. 85,71-80 (2002).
30. Gore M. Carboplatin equals cisplatin: but how do I prescribe it? J. Clin. Oncol. 17, 3183-3185 (2003).
31. Vasey P. Survival and longer-term toxicity results of the SCOTROC study: docetaxel-carboplatin vs. paclitaxel-carboplatin in epithelial ovarian cancer. Proc. Am. Soc. Clin. Oncol. 21, 202a (2002) (Abstract 804).
32. Alberts DS, Liu PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for Stage III ovarian cancer. N. Engl. J. Med. 335, 1950-1955 (1996).
33. Markman M, Bundy BN, Alberts DS et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume Stage III ovarian carcinoma: an Intergroup Study of the GOG, SWOG and ECOG. J. Clin. Oncol. 19, 1001-1007 (2001).
34. Armstrong DK, Bundy BN, Baergen R et al. Randomized Phase III study of intravenous paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal cisplatin and IP paclitaxel in optimal Stage III epithelial ovarian cancer a Gynecologic Oncology Group trial (GOG 172). Proc. Am. Soc. Clin. Oncol. 21, 201a (2002) (Abstract 803).
35. Alberts D, Markman M, Armstrong D et al. Intraperitoneal therapy for Stage III ovarian cancer: a therapy whose time has come! J. Clin. Oncol. 20, 3944-3946 (2002).
36. González Martín A, López García M, García Martínez H et al. Futuras líneas de investigación en cáncer de ovario. Rev. Oncologia 15(5), 28-36 (2001).
37. Markman M, Liu PY, Wilczynski S et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J. Clin. Oncol. 21, 2460-2465 (2003).
38. Cure H, Battista C, Guastalla J et al. Phase III randomized trial of high-dose chemotherapy and peripheral blood stem cell support as consolidation in patients with advanced ovarian cancer: 5-year follow-up of a GINECO/FNCLCC/ SFGM-TC study. Proc. Am. Soc. Clin. Oncol. 23 (2004) (Abstract 5006).
39. Markman M, Rothman R, Hakes T et al. Second line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9, 389-393 (1991).
40. Thipgen JT, Vance RB, Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 71, 1559-1564 (1993).
41. Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J. Clin. Oncol. 10, 513-514 (1992).
42. Sabbatini P, Spriggs D. Salvage therapy for ovarian cancer. Oncology 12, 833-851 (1998).
43. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann. Oncol. 10 (1), S87-S92 (1999).
44. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann. Oncol. 8, 963-968 (1997).
45. Cantú MG, Buda A, Parma G et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J. Clin. Oncol. 20, 1232-1237 (2002).
46. Bolis G, Scarfone G, Villa A et al. Carboplatin alone vs. carboplatin plus epidoxorrubicin as second-line therapy for cisplatin or carboplatin-sensitive ovarian cancer. Gynecol. Oncol. 91, 3-9 (2001).
47. Markman M. Single agent carboplatin is the treatment of choice in recurrent, potentially platinum-sensitive ovarian cancer. Am. Soc. Clin. Oncol. Education Book, 38th Annual Meeting 521-523 (2002).
48. Guastalla JP, Pujade-Lauraine E, Weber H et al. Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. A multicenter GINECO Phase II study. Ann. Oncol. 9, 37-43 (1998).
49. Rose P, Fusco N, Fluellen L et al. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J. Clin. Oncol. 16, 1494-1497 (1998).
50. Gronlund B, Hogdall C, Hansen HH et al. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. Gynecol. Oncol. 83, 128-134 (2001).
51. Dizon D, Hensley M, Sabbatini P et al. Carboplatin and paclitaxel as initial second line therapy in recurrent epithelial ovarian carcinoma. Proc. Am. Soc. Clin. Oncol. 20, 203a (2001) (Abstract 809).
52. Bolis G, Scarfone G, Csiatta C et al. A Phase I/II study of topotecan in combination with carboplatin in recurrent epithelial ovarian cancer. Gynecol. Oncol. 83, 477-480 (2001).
53. Du Bois A, Luck HJ, Pfisterer J et al. Second line carboplatin and gemcitabine in platinum sensitive ovarian cancer: a dose finding study by the AGO Ovarian Cancer Study Group. Ann. Oncol. 12, 1115-1120 (2001).
54. Ferrero J, Weber B, Lepille D et al. Caelyx and carboplatin in patients with advanced ovarian cancer in late relapse (>6 months): late results a GINECO Phase II trial. Proc. Am. Soc. Clin. Oncol. 23, 453 (2004) (Abstract 5022).
55. Viens P, Bougnoux P, Dieras V et al. A Phase II trial of oxaliplatin and paclitaxel combination in advanced ovarian cancer patients pretreated with cisplatin or carboplatin ± taxanes: preliminary results. Proc. Am. Soc. Clin. Oncol. 21,223a (2002) (Abstract 889).
56. The ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361, 2099-106 (2003).
57. Gonzalez-Martín A, Calvo E, Bover I et al. Randomised Phase II study of carboplatin versus paclitaxel-carboplatin in platinum-sensitive recurrent advanced ovarian cancer: a GEICO study. Proc. Am. Soc. Clin. Oncol. 22, 451 (2003) (Abstract 1812).
58. Pfisterer J, Plante M, Vergote I et al. Gemcitabine/carboplatin vs. carboplatin in platinum sensitive recurrent ovarian cancer. Results of a Gynecologic Cancer Intergroup randomized Phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. Proc. Am. Soc. Clin. Oncol. 23, 449 (2004) (Abstract 5005).
59. McGuire W. Management of the patient with recurrent ovarian cancer. Am. Soc. Clin. Oncol. Education Book, 38th Annual Meeting 530-532 (2002).
60. Kavanagh J, Tresukosol D, Edwards C et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J. Clin. Oncol. 13, 1584-1588 (1995).
61. Mc Guire WP, Blessing JA, Bookman MA et al. Topotecan has substantial antitumor activity as first line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 18, 1062-1067 (2000).
62. Rose PG, Blessing JA, Mayer AR et al. Prolonged oral etoposide as second line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 16, 405-410 (1998).
63. Vermorken J, Gore M, Perren T et al. Multicenter randomised Phase II study of oxaliplatin or topotecan in platinum-pretreated epithelial ovarian cancer patients. Proc. Am. Soc. Clin. Oncol. 20, 212a (2001) (Abstract 847).
64. Ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. 15, 2183-2193 (1997).
65. Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomised Phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19, 3312-3322 (2001).
66. Kaye SB. Chemotherapy for recurrent ovarian cancer. Lancet 361, 2094-2095 (2003).
67. Gore M. Treatment of relapsed epithelial ovarian cancer. Am. Soc. Clin. Oncol. Education Book 468-476 (2001).
68. Markman M, Hall J, Spitz D et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J. Clin. Oncol. 20, 2365-2369 (2002).
69. Piccart M, Green J, Lacave A et al. Oxaliplatin or paclitaxel in patients with platinum pretreated advanced ovarian cancer: a randomised Phase II study of the EORTC of Cancer Gynecology Group. J. Clin. Oncol. 18, 1193-1202 (2000).
70. Vermorken J, Gore M, Perren T et al. Multicenter Randomized Phase II study of oxaliplatin or topotecan in platinum-pretreated epithelial ovarian cancer patients. Proc. Am. Soc. Clin. Oncol. 20, 212a (2001) (Abstract 847).
71. Rosenberg P, Anderson H, Boman K et al. A randomised multicenter study of single agent paclitaxel given weekly versus every three weeks to patients with ovarian cancer previously treated with platinum therapy. Proc. Am. Soc. Clin. Oncol. 18, 368a (1999) (Abstract 1420).